Sanegene Bio is a clinical-stage, fully integrated biotechnology company backed by a syndicate of private equity investors. We are focused on discovering and developing best-in-class genetic medicines for obesity, cardiometabolic, and autoimmune diseases using RNA interference (RNAi) technology. Founded in 2021 by industry veterans with deep RNAi expertise, SanegeneBio is headquartered in Boston, with R&D operations in both the U.S. and China. Our proprietary technology platform, LEAD™ (Ligand and Enhancer Assisted Delivery), enables tissue-specific silencing of disease-driving genes in the liver, adipose tissue, muscle, and immune cells-achieved through safe, infrequent subcutaneous dosing. Sanegene Bio is committed to advancing transformative RNAi therapies that address global unmet medical needs.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 12/19/25 | $110,000,000 | Series B |
China Biopharma Eli Lilly and Company Hillhouse Capital Group Legend Capital Qiming Venture Partners | undisclosed |
